Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
about
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyOncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in miceOsteoimmunology: interactions of the bone and immune systemHormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1The molecular mechanism of osteoclastogenesis in rheumatoid arthritisThe Alternative Faces of Macrophage Generate OsteoclastsAnimal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewHistorically significant events in the discovery of RANK/RANKL/OPGMultiple organ dysfunction and systemic inflammation after spinal cord injury: a complex relationshipThe biology and clinical evidence of microfracture in hip preservation surgeryTransmembrane domain of gp130 contributes to intracellular signal transduction in hepatic cellsCiliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodelingInduction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritisSoluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responsesThe anti-aging effects of LW-AFC via correcting immune dysfunctions in senescence accelerated mouse resistant 1 (SAMR1) strainAttenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice.Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularizationInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An UpdateThe Kampo medicine Rokumigan possesses antibiofilm, anti-inflammatory, and wound healing properties.Rheumatoid Arthritis Fibroblast-like Synoviocyte Suppression Mediated by PTEN Involves Survivin Gene Silencing.Soluble cytokine receptors: basic immunology and clinical applications.The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells.Association between inflammatory biomarkers and bone mineral density in a community-based cohort of men and womenA histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B geneAnti-interleukin 6 receptor antibody treatment in rheumatic disease.Addition of aerobic exercise to a weight loss program increases BMD, with an associated reduction in inflammation in overweight postmenopausal womenInterleukin-6 and rheumatic diseases.Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow.Role of the osteoclast at the bone-implant interface.Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.gp130 at the nexus of inflammation, autoimmunity, and cancer.The therapeutic potential of interleukin-6 hyperagonists and antagonists.Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis.gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cellsPopulation differences in proinflammatory biology: Japanese have healthier profiles than Americans.The biochemical origin of pain--proposing a new law of pain: the origin of all pain is inflammation and the inflammatory response. Part 1 of 3--a unifying law of painSOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis.The paradigm of IL-6: from basic science to medicine
P2860
Q24630541-41718738-242A-41ED-8FCE-7B1DA1C16BBEQ24642117-16A7FB20-4D20-49B0-AC87-2810502FC921Q24655113-5310BF95-E77A-438A-8153-90D15E468292Q24804802-BB1C8110-FF78-4850-A0F0-412CCE598BCCQ24806322-242E719A-DEC8-4330-98AB-ECBB9FE13EDDQ26765491-C509AD89-1F9C-4F27-A5E6-55AB2D98A7C0Q26774874-F3C81C15-EDEB-42D1-9456-028F6BAEC068Q27027402-21DA2E85-2037-4796-858A-1A31B8BF6F2AQ28066958-25FFD048-6EF1-4093-8C8C-DEF18399B27BQ28072782-BB02C3B9-934C-4A5F-99B3-8EFD15B1990EQ28255702-D1F67E5A-3CFE-4671-B34D-39E33F3A31D1Q28273257-123F2CC0-B01B-4CBA-9566-4721794168DAQ28366650-A1EDC40C-77FC-4CAD-ABA8-853E3C4B45BDQ28634282-1CE4C866-18DF-42E1-8A97-91C9DA189BAFQ30819335-1CCFA908-1F65-4EF9-AE2C-8234FDE0FCD4Q30827854-83859A9A-C9B7-47CE-8195-42AB1959C393Q33285746-28ED7EB0-A72B-41B2-9519-631B1DB58C61Q33586501-D719E0CF-0428-4965-881B-372727EEFF10Q33615873-524E20EC-33C6-452E-8189-F357E6B7329CQ33673624-36708695-F0D8-4BB6-B861-355926A31035Q33688222-F8EE7583-85E9-460E-81D1-1AA90E6C88C8Q33731751-4B997798-FB56-417C-8378-9FC3E7805EF5Q33767224-1F5731AE-E63F-40B8-8DB0-5E20E4F2DBE6Q33800888-1EE194F9-071F-4BF5-A217-310AD068CC41Q33853660-9D757AA1-9396-46B7-BAA5-C0839219CCAEQ34071253-9A15AFD1-46C0-4576-A003-FA1A8ECC0AE9Q34080333-5F06A542-0F72-49EE-B905-917401334F05Q34160235-0C1DE619-FD87-46E5-A08A-C781B3AC33C5Q34183981-388082C8-8BEC-4770-B8E1-5A8BB2A71212Q34200518-9296999E-692D-401E-A367-EA08D2D0B635Q34270015-F90CAAF3-DC28-4A71-99B3-27500B7D9207Q34343286-38AE83AD-AE36-4CBF-A11E-3AD1B2ABD011Q34378756-F1CA039A-CC9E-4E7C-9658-489D2BBFC379Q34430168-956B264B-573F-48BE-A202-A801AE262B16Q34501230-8EDEF577-A674-441F-8547-6EBCF74DA0D1Q34510302-6177AF94-118E-4FAA-B272-53B744FCC141Q34574670-907DCE5F-B92E-41D8-9AD9-0BFFE7B01D96Q34604663-7322C9B0-7E5B-48BD-B56D-F633931F3395Q34619592-8DC2A994-66EA-4D3F-81B5-FE7F0FD84B9AQ34731226-305D3F78-431D-47A1-8CD9-9092E46FC5DD
P2860
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@ast
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@en
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@nl
type
label
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@ast
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@en
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@nl
prefLabel
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@ast
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@en
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@nl
P2093
P2860
P3181
P356
P1476
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6
@en
P2093
N Takahashi
Y Koishihara
P2860
P304
P3181
P356
10.1073/PNAS.90.24.11924
P407
P577
1993-12-15T00:00:00Z